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background:  Gender differences in coronary artery disease (CAD) evolution, and overlap in etiologies of CAD and progressive tricuspid 
aortic stenosis (trileafletAS), suggest also gender differences during the natural progression of trileafletAS. We aimed to explore those 
differences in a healthy older cohort newly diagnosed with trileafletAS.
methods and results:  Exploratory clinical-based cohort study of 293 consecutive trileafletAS pts (age 70.9±10.9 yrs., 43.7 % female) 
without cardiac co-morbidities, identified during initial confirmatory echo diagnosis, followed up for 6.5±3.4 yrs for competing outcomes of 
heart failure (HF), aortic valve (AV) replacement (AVR), and death. 109 pts received AVR-s, 94 pts developed Incident HF, and 102 died. 
Compared to men, women showed higher hazard ratio of incident HF [age-adjusted HR=1.9; 95% CI (1.1-3.5)] (competing parametric 
model for AVR, HF and mortality), especially non-ischemic incident HF, and were less likely to die after receiving AVR .
Conclusion:  We identified gender differences following the diagnostic and clinical expression of trileafletAS without cardiac comorbidities. 
Further studies should clarify the pathophysiological mechanisms associated with these differences, address the benefits of gender-specific 
risk scores for predicting outcomes in this population, and explore the potential benefits of gender specific diagnosis approaches, follow-up, 
and therapy.
 
